Suspension from Quotation
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Cynata Therapeutics Limited has requested a voluntary suspension of its securities from quotation pending the release of significant announcements regarding clinical trial results. The suspension is effective immediately and will remain until the earlier of the announcement release or the end of the specified period. Cynata expects to announce these results shortly, by the end of the specified period.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Cynata Therapeutics Limited on 6ix
Earlier from Cynata Therapeutics
- EU Positive Opinion on CYP-001 Paediatric Investigation Plan
- Cynata Secures Commitments for $1.5m Placement
- March 2026 Quarterly Activity Report & Appendix 4C
- Last Visit in GvHD Trial Completed
- Appendix 4D & Half-Year Financial Statements
Later from Cynata Therapeutics
- CYP-001 GvHD Trial Primary Evaluation Results
- Reinstatement to Official Quotation
- Board, Management Changes, Expenditure Reductions, RDTI Loan
- June 2026 Quarterly Activity Report & Appendix 4C
- Appendix 4E & Preliminary Final Report
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics